胸苷激酶1在胸腔积液鉴别诊断中的作用研究

doi:10.3969/j.issn.1000-8535.2019.03.015

广州医药 ›› 2019, Vol. 50 ›› Issue (3): 56-60.DOI: 10.3969/j.issn.1000-8535.2019.03.015

胸苷激酶1在胸腔积液鉴别诊断中的作用研究

程江涛, 刘清毅, 杨印楼, 张宏华, 马占忠, 尹迎秋, 龚梅

韶关市粤北人民医院呼吸内科(韶关 512026)

收稿日期:2019-01-08 出版日期:2019-05-20 发布日期:2021-12-17
通讯作者: 程江涛,E-mail: 46573320@qq.com

The role of thymidine kinase1 play in distinguishing pleural effusions

CHENG Jiangtao, LIU Qingyi, YANG Yinlou, ZHANG Honghua, MA Zhanzhong, YIN Yingqiu, GONG Mei

Respiratory Medicine Department, Yue bei People's Hospital, Shaoguan 512026, China

Received:2019-01-08 Online:2019-05-20 Published:2021-12-17

摘要/Abstract

摘要： 目的探讨胸苷激酶1活性检测在胸腔积液鉴别诊断中的敏感度及特异度。方法回顾性分析诊断明确的肺炎旁胸腔积液、结核性胸腔积液、癌性胸腔积液患者的临床资料,收集并检测三组患者胸腔积液标本中胸苷激酶1活性并进行比较。结果三组胸腔积液胸苷激酶1含量分别为: 肺炎旁胸腔积液组: (1.18±0.73)pmol/L、结核组活性(1.31±0.64)pmol/L、癌性组(2.07±1.47)pmol/L。统计分析显示癌性组胸苷激酶1含量高于肺炎旁胸腔积液组及结核组,差异有统计学意义,而肺炎旁组与结核组胸苷激酶1含量无统计学差异。在诊断价值分析方面,当胸苷激酶1≥1.28 pmol/L时支持癌性胸腔积液诊断,但是当胸苷激酶1＜1.28 pmol/L时,无法鉴别肺炎旁和结核性胸腔积液。因此,胸苷激酶1对于癌性胸腔积液的诊断价值较好,对肺炎旁胸腔积液和结核性胸腔积液鉴别诊断效能差。临床可考虑与其他指标,如降钙素原、腺苷脱氨酶等指标联合诊断。结论胸腔积液胸苷激酶1含量在癌性胸腔积液与非癌性胸腔积液的鉴别诊断中有较好诊断价值。

关键词: 胸苷激酶1, 肺炎旁胸腔积液, 结核性胸腔积液, 癌性胸腔积液

Abstract: Objective To investigate the of thymidine kinase 1in differential diagnosis of pleural effusion. Methods A retrospective analysis of thymidine kinase1 activity in the parapneumonic pleural effusion and tuberculous pleural effusion and malignant pleural effusion were conducted. Results The thymidine kinase 1 of this three groups are respectively: parapneumonic group (1.18±0.73pmol/L), tuberculosis group (1.31±0.64pmol/L), and cancer group (2.07±1.47pmol/L). It was shown that the activity of thymidine kinase 1 in cancer group was higher than that of inflammation group and tuberculosis group, the difference was statistical significance, but there was no significant difference between parapneumonic group and tuberculosis group. It supported the diagnosis of malignant pleural effusion when thymidine kinase 1 was greater than or equal to 1.28pmol/L, but when the thymidine kinase 1 was less than 1.28pmol/L, it was impossible to distinguish parapneumonic pleural effusion and tuberculous pleural effusion. Therefore, the diagnosis efficiency of thymidine kinase 1 in malignant pleural effusion is well, but the diagnosis efficiency of thymidine kinase 1 in parapneumonic pleural effusion and tuberculous pleural effusion is not well. Conclusion The diagnosis efficiency of thymidine kinase 1 in malignant pleural effusion and non-malignant pleural effusion is well.

Key words: Thymidine kinase 1, Parapneumonic effusion, Tuberculous pleural effusion, Cancerous pleural effusion

程江涛, 刘清毅, 杨印楼, 张宏华, 马占忠, 尹迎秋, 龚梅. 胸苷激酶1在胸腔积液鉴别诊断中的作用研究[J]. 广州医药, 2019, 50(3): 56-60.

CHENG Jiangtao, LIU Qingyi, YANG Yinlou, ZHANG Honghua, MA Zhanzhong, YIN Yingqiu, GONG Mei. The role of thymidine kinase1 play in distinguishing pleural effusions[J]. Guangzhou Medical Journal, 2019, 50(3): 56-60.

参考文献

[1] 施焕中. 重视胸腔积液的基础与临床研究 [J]. 中华结核和呼吸杂志,2013,36(5): 323-324.
[2] AUFDERKLAMM S,TODENHöFER T,GAKIS G,et al. Thymidine kinase and cancer monitoring [J]. Cancer Letters, 2012, 316(1): 6-10.
[3] JAGARLAMUDI K K,HANSSON L O,ERIKSSON S. Breast and prostate cancer patients differ significantly in their serum thymidine kinase 1 (tk1) specific activities compared with those hematological malignancies and blood donors: Implications of using serum tk1 as a biomarker [J]. Bmc Cancer,2015, 15(1): 1-12.
[4] MOLINA R,AUGé J M,BOSCH X,et al. Usefulness of serum tumor markers, including progastrin-releasing peptide,in patients with lung cancer: Correlation with histology [ J]. Tumour Biol,2009,30 (3): 121-129.
[5] DAVIES H E,DAVIES R J,DAVIES C W. Management of pleural infection in adults: British thoracic society pleural disease guideline 2010 [J]. Thorax,2010,65(suppl 2): ii41-ii53.
[6] WONG C F,YEW W W,LEUNG S K,et al. Assay of pleural fluid interleukin-6,tumour necrosis factor-alpha and interferongamma in the diagnosis and outcome correlation of tuberculous effusion [J]. Respir Med,2003,97(12): 1289-1295.
[7] LIGHT R W. Update on tuberculous pleural effusion [J]. Respirol,2010,15(3): 451-458.
[8] HEFFNER J E,BROWN L K,BARBIERI C A. Diagnostic value of tests that discriminate between exudative and transudative pleural effusions [J]. Chest,1997,111(4): 970-980.
[9] CARLSSON L, LARSSON A. Elevated levels of thymidine kinase 1 pepfide in serum from patients with breast cancer [J]. Ups J Med Sci, 2009, 144(2): 116-120.
[10] MUTAHIR Z, CLAUSEN A R, ANDERSSOn K M, et al. Thymidine kinase 1 regulatory fine-tuning throughtetramer formation [J]. FEBS J, 2013, 280(6): 1531-1541.
[11] KIRANKUMAR J, SHARIF H, WESTBERG S, et al. High levels of inactive thymidine kinase 1 polypeptide detected in sera from dogs with solid tumours by immunoaffinity methods: implications for in vitro diagnostics [J]. Vet J, 2013, 197(3): 854-860.
[12] AGARWAL H K, MCELROY C A, SJUVARSSON E, et al. Synthesis of N3substitutedcarboranyl thymidine bioconjugates and their evaluation as substrates of recombinant human thymidine kinase 1 [J]. Eur J Med Chem, 2013,60(2): 456-468.
[13] NISMAN B, APPELBAUM L, YUTKIN V, et al. Serum thymidine kinase 1 activity following nephrectomy for renal cell carcinoma and radiofrequency ablation of metastases to lung and liver [J]. Anticancer Res, 2016,36(4): 1791-1797.
[14] CHEN G, HE C, LI L, et al. Nuclear TK1 expression is an independent prognostic factor for survival in pre-malignant and malignant lesions of the cervix [J]. BMC Cancer, 2013,13: 249.
[15] JAGARLAMUDI K K, HANSSON L O, ERIKSSON S. Breast and prostate cancer patients differ significantly in their serum Thymidine kinase 1 (TK1) specific activities compared with those hematological malignancies and blood donors: implications of using serum TK1 as a biomarker [J]. BMC Cancer, 2015,15(66): 126-138.
[16] ALEGRE M M, ROBISON R A, O'NEILL K L. Thymidine kinase 1 upregulation is an early event in breast tumor formation [J]. J Oncol, 2012,22(3): 1-5.
[17] KEMIK O, KEMIK A S, PURISA S, et al. Serum thymidine kinase is associated with gastricadeno carcinoma [J]. Bratisl Lek Listv, 2011, 112(9): 510-511.
[18] BROCKENBROUGH J S, MORIHARA J K, HAWES S E, et al. Thymidine kinase 1 and thymidine phosphorylase expression in non-small-cell lung carcinoma in relation to angiogenesis and proliferation [J]. J Histochem Cytochem,2009,57(11): 1087-1097.
[19] 张伟,龚磊杨,锦雷,等. 血清胸苷激酶1在食管鳞癌诊治中的应用价值 [J]. 安徽医学杂志 [J],2018,39(9): 1125-1127.
[20] 田果平.血清胸苷激酶1(TK1)水平变化对小细胞肺癌(NSCLC)患者临床诊断价值观察临床医药文献电子杂志 [J]. 2018,(72): 156-159.
[21] WEAGEL E G, MENG W, TOWNSEND M H, et al. Biomarker analysis and clinical relevance of TK1 on the cell membrane of Burkitt's lymphoma and acute lymphoblastic leukemia [J]. Onco Targets and Therapy, 2017,10: 4335-4367.
[22] WEI Y T, LUO Y Z, FENG Z Q, et al. TK1 overexpression is associated with the poor outcomes of lung cancer patients: a systematic review and meta-analysis [J]. Biomark Med, 2018,12(4):403-413.
[23] GASPARRI F, WANG N, SKOG S, et al. Thymidine kinase 1 expression defines an activated G1 state of the cell cycle as revealed with site-specific antibodies and ArrayScan assays [J]. Eur J Cell Biol, 2009,88(12):779-785.

胸苷激酶1在胸腔积液鉴别诊断中的作用研究

The role of thymidine kinase1 play in distinguishing pleural effusions

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

编辑推荐

Metrics

本文评价